Surfactant "fortification" by topical inhibition of nuclear factor-κB activity in a newborn piglet lavage model

Critical Care Medicine

Volumn 35, Issue 10, 2007, Pages 2309-2318

  Von Bismarck, Philipp ^a   Klemm, Karsten ^a   Wistädt, Carlos Francisco García ^a   Winoto Morbach, Supandi ^a   Uhlig, Ulrike ^b   Schütze, Stefan ^a   Uhlig, Stefan ^b   Lachmann, Burkhard ^c   Krause, Martin F ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Acid sphingomyelinase; Ceramide; Fortified surfactant; Lung edema; Neonatal acute respiratory distress syndrome; Surface tension

Indexed keywords

CERAMIDE; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SPHINGOMYELIN PHOSPHODIESTERASE; SURFACTANT; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; BIOLOGICAL MONITORING; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; EX VIVO STUDY; EXPERIMENTAL MODEL; EXPERIMENTAL PIG; GAS EXCHANGE; LEUKOCYTE; LUNG COMPLIANCE; LUNG EDEMA; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG LAVAGE; NEWBORN; NONHUMAN; OXYGEN TENSION; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RELAPSE; RESPIRATORY SYSTEM; RESPIRATORY TRACT PARAMETERS; SURFACE TENSION; TREATMENT OUTCOME;

ANIMALS; ANIMALS, NEWBORN; HUMANS; INFANT, NEWBORN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NF-KAPPA B; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SURFACE-ACTIVE AGENTS; SWINE;

EID: 34748891179     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000281472.47067.45     Document Type: Article

References (59)

1. Hallman M, Spragg R, Harrell JH, et al: Evidence of lung surfactant abnormality in respiratory failure: Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982; 70:673-683
2. Gregory TJ, Longmore WJ, Moxley MA, et al: Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88:1976-1981
3. Carlton DP, Cho SC, Davis P, et al: Surfactant treatment at birth reduces lung vascular injury and edema in preterm lambs. Pediatr Res 1995; 37:265-270
4. Flemmer A, Simbruner G, Muenzer S, et al: Effect of lung water content, manipulated by intratracheal furosemide, surfactant, or a mixture of both, on compliance and viscoelastic tissue forces in lung lavaged newborn piglets. Crit Care Med 2000; 28:1911-1917
5. Krause MF, Wiemann T, Reisner A, et al: Surfactant reduces extravascular lung water and invasion of polymorphonuclear leukocytes into the lung in a piglet model of airway lavage. Pulm Pharmacol Ther 2005; 18:129-139
6. Van Iwaarden JF, Claassen E, Jeurissen SHM, et al: Alveolar macrophages, surfactant lipids, and surfactant protein B regulate the induction of immune responses via the airways. Am J Respir Cell Mol Biol 2001; 24:452-458
7. Wu Y-Z, Medjane S, Chabot S, et al: Surfactant protein-A and phosphatidylglycerol suppress type IIA phospholipase A2 synthesis via nuclear factor-kappa B. Am J Respir Crit Care Med 2003; 168:692-699
8. Haitsma JJ, Uhlig S, Lachmann U, et al: Exogenous surfactant reduces ventilator-induced decompartmentalization of tumor necrosis factor alpha in absence of positive end-expiratory pressure. Intensive Care Med 2002; 28:1131-1137
9. Royall JA, Levin DL: Adult respiratory distress syndrome in pediatric patients: I. Clinical aspects, pathophysiology, pathology, and mechanisms of lung injury. J Pediatr 1988; 112:169-180
10. Paulson TE, Spear RM, Peterson BM: New concepts in the treatment of children with acute respiratory distress syndrome. J Pediatr 1995; 127:163-175
11. 4 mediates histamine induction of NF-κB and IL-8 in human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 1998; 274:L1030-L1039
12. Christman JW, Sadikot RT, Blackwell TS: The role of nuclear factor-kappaB in pulmonary diseases. Chest 2000; 117:1482-1487
13. Zingarelli B: Nuclear factor-kappaB. Crit Care Med 2005; 33(Suppl):S414-S416
14. Iuvone T, D'Acquisto F, Van Osselaer N, et al: Evidence that inducible nitric oxide synthase is involved in LPS-induced plasma leakage in rat skin through the activation of nuclear factor-kappaB. Br J Pharmacol 1998; 123:1325-1330
15. Ankermann T, Reisner A, Wiemann T, et al: Topical inhibition of nuclear factor-κB enhances reduction in lung edema by surfactant in a piglet model of airway lavage. Crit Care Med 2005; 33:1384-1391
16. Krause MF, Jäkel C, Haberstroh J, et al: Alveolar recruitment promotes homogeneous surfactant distribution in a piglet model of lung injury. Pediatr Res 2001; 50:34-43
17. Krause MF, Hoehn T: Decrease in lung volume depends on end-expiratory pressure in a rabbit model of airway lavage. Respiration 1999; 66:259-264
18. Kelly KP, Stenson BJ, Drummond GB: Randomised comparison of partial liquid ventilation, nebulised perfluorocarbon, porcine surfactant, artificial surfactant, and combined treatments on oxygenation, lung mechanics, and survival in rabbits after saline lung lavage. Intensive Care Med 2000; 26:1523-1530
19. Zhou Z-H, Sun B, Lin K, et al: Prevention of rabbit acute lung injury by surfactant, inhaled nitric oxide, and pressure support ventilation. Am J Respir Crit Care Med 2000; 161:581-588
20. Zhu Y, Guo C, Gong X, et al: Different effects of surfactant and inhaled nitric oxide in modulation of inflammatory injury in ventilated piglet lungs. Pulm Pharmacol Ther 2005; 18:303-313
21. Nimmo AJ, Carstairs JR, Patole SK, et al: Intratracheal administration of glucocorticoids using surfactant as a vehicle. Clin Exp Pharmacol Physiol 2002; 29:661-665
22. Suntres ZE, Shek PN: Liposomes promote pulmonary glucocorticoid delivery. J Drug Target 1998; 6:175-182
23. Yamaoka S, Courtois G, Bessia C, et al: Complementation cloning of NEMO, a component of the I kappa B kinase complex essential for NF-kappa B activation. Cell 1998; 93:1231-1240
24. IKK-NBD peptide, catalog no. P-607.l [package insert]. Plymouth Meeting, PA, Biomol Research Laboratories, 2003
25. Notter RH, Egan EA, Kwong MS, et al: Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: Effects of dose, dispersion technique, and gestational age. Pediatr Res 1985; 19:569-577
26. Schiffmann H, Erdlenbruch B, Singer D, et al: Assessment of cardiac output, intravascular volume status, and extravascular lung water by transpulmonary indicator dilution in critically ill neonates and infants. J Cardiothorac Vasc Anesth 2002; 16:592-597
27. Krause MF, Orlowska-Volk M, Hendrik ER, et al: A new simple method of staining exogenous surfactant in experimental research. Eur Respir J 2000; 15:949-954
28. Wiegmann K, Schütze S, Machleidt T, et al: Functional dichotomy of neutral and acidic sphingomyelinase in tumor necrosis factor signaling. Cell 1994; 78:1005-1015
29. Jensen JM, Schütze S, Förl M, et al: Roles for tumor necrosis receptor p55 and sphingomyelinase in repairing the cutaneous permeability barrier. J Clin Invest 1999; 104:1761-1770
30. Andrews NC, Faller DV: A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991; 19:2499
31. Cao L, Qian LL, Zhu YR, et al: Regulation of activity of nuclear factor-kappaB and activator protein-1 by nitric oxide, surfactant, and glucocorticoids in alveolar macrophages from piglets with acute lung injury. Acta Pharmacol Sin 2003; 24:1316 -1323
32. Finck CM, Hodell MG, Marx WH, et al: Endotoxin-stimulated alveolar macrophage recruitment of neutrophils and modulation with exogenous surfactant. Crit Care Med 1998; 26:1414-1418
33. Suwabe A, Otake K, Yakuwa N, et al: Artificial surfactant (surfactant TA) modulates adherence and superoxide production of neutrophils. Am J Respir Crit Care Med 1998; 158:1890-1899
34. 4-surfactant in models of meconium aspiration syndrome. Pediatr Res 1998; 44:705-715
35. Ikegami M, Jobe AH: Injury responses to different surfactants in ventilated premature lamb lungs. Pediatr Res 2002; 51:689-695
36. Reiss I, Kuntz S, Schmidt R, et al: Effects of pulmonary surfactant on TNF-alpha-activated endothelial cells and neutrophil adhesion in vitro. Immunobiology 2004; 209:235-244
37. Davis JM, Rosenfeld WN, Koo HC, et al: Pharmacologic interactions of exogenous lung surfactant and recombinant human Cu/Zn superoxide dismutase. Pediatr Res 1994; 35:37-40
38. Zingarelli B, Sheehan M, Wong HR: Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med 2003; 31(Suppl):S105-S111
39. Christman JW, Lancaster LH, Blackwell TS: Nuclear factor kappa B: A pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med 1998; 24:1131-1138
40. Vancurova I, Bellani P, Davidson D: Activation of nuclear factor-kappaB and its suppression by dexamethasone in polymorphonuclear leukocytes: Newborn versus adult. Pediatr Res 2001; 49:257-262
41. Fan J, Malik AB: Toll-like receptor-4 (TLR4) signaling augments chemokine-induced neutrophil migration by modulating cell surface expression of chemokine receptors. Nat Med 2003; 9:315-321
42. Zhou X, Gao XP, Fan J, et al: LPS activation of toll-like receptor 4 signals CD11b/CD18 expression in neutrophils. Am J Physiol Lung Cell Mol Physiol 2004; 288:655-662
43. Everhart MB, Han W, Sherill TP, et al: Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury. J Immunol 2006; 176:4995-5005
44. Mathias S, Pena LA, Kolesnick RN: Signal transduction of stress via ceramide. Biochem J 1998; 335:465-480
45. Newton R, Hart L, Chung KF, et al: Ceramide induction of COX-2 and PGE(2) in pulmonary A549 cells does not involve activation of NF-kappaB. Biochem Biophys Res Commun 2000; 277:675-679
46. Chen CC, Sun YT, Chen JJ, et al: Tumor necrosis factor-alpha-induced cyclooxygenase-2 expression via sequential activation of ceramide-dependent mitogen-activated protein kinases, and IkappaB kinase 1/2 in human alveolar epithelial cells. Mol Pharmacol 2001; 59:493-500
47. Vivekananda J, Smith D, King RJ: Sphingomyelin metabolites inhibit sphingomyelin synthase and CTP: Phosphocholine cytidylyl-transferase. Am J Physiol Lung Cell Mol Physiol 2001; 281:L98-L107
48. Rauvala H, Hallman M: Glycolipid accumulation in bronchoalveolar space in adult respiratory distress syndrome. J Lipid Res 1984; 25:1257-1262
49. Carroll JL Jr, McCoy DM, McGowan SE, et al: Pulmonary-specific expression of tumor necrosis factor-alpha alters surfactant lipid metabolism. Am J Physiol Lung Cell Mol Physiol 2002; 282:L735-L742
50. Ryan AJ, McCoy DM, McGowan SE, et al: Alveolar sphingolipids generated in response to TNF-alpha modifies surfactant biophysical properties. J Appl Physiol 2003; 94:253-258
51. Göggel R, Winoto-Morbach S, Vielhaber G, et al: PAF-mediated pulmonary edema: A new role for acid sphingomyelinase and ceramide. Nat Med 2004; 10:155-160
52. Spragg RG, Smith RM: Pathology of the surfactant system of the mature lung. Am J Respir Crit Care Med 1997; 155:756-760
53. Lu KW, Goerke J, Clements JA, et al: Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatr Res 2005; 58:206-210
54. Kobayashi T, Ohta K, Tashiro K, et al: Dextran restores albumin-inhibited surface activity of pulmonary surfactant extracts. J Appl Physiol 1999; 86:1778-1784
55. Lu KW, Taeusch HW, Robertson B: Polyethylene glycol/surfactant mixtures improve lung function after HCl and endotoxin lung injuries. Am J Respir Crit Care Med 2001; 164:1531-1536
56. Rüdiger M, Kolleck I, Putz G, et al: Plasmalogens effectively reduce the surface tension of surfactant-like phospholipid mixtures. Am J Physiol Lung Cell Mol Physiol 1998; 274:L143-L148
57. Belai Y, Hernandez-Juviel JM, Bruni R, et al: Addition of alpha1-antitrypsin to surfactant improves oxygenation in surfactant-deficient rats. Am J Respir Crit Care Med 1999; 159:917-923
58. May MJ, D'Acquisto F, Madge LA, et al: Selective inhibition of NF-kappa B activation by a peptide that blocks the interaction of NEMO with the I kappa B kinase complex. Science 2000; 289:1550-1554
59. di Meglio P, Ianaro A, Ghosh S: Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum 2005; 52:951-958